Thrombocythemia 2: genes and variants
Explore variant evidence for Thrombocythemia 2 across 4 analyzed proteins (MPL, JAK2, SH2B3, CALR). Linked ClinVar records include 9 pathogenic or likely pathogenic variants, 18 variants of uncertain significance and 3 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-04. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Thrombocythemia 2
MPL: Thrombopoietin receptor
Thrombopoietin signaling through this pathway drives megakaryocyte maturation, platelet production, and hematopoietic stem-cell maintenance. Activating variants can cause myeloproliferative neoplasms or hereditary thrombocytosis, whereas loss-of-function variants cause congenital amegakaryocytic thrombocytopenia.
7 ClinVar pathogenic / likely pathogenic and 4 uncertain variants in MPL have source records linked to Thrombocythemia 2. Association strength is not clinical gene validity.
JAK2: Tyrosine-protein kinase JAK2
It transmits signals from erythropoietin, thrombopoietin, growth hormone, and other cytokine receptors into STAT-dependent transcription. The V617F gain-of-function variant is a major driver of polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
2 ClinVar pathogenic / likely pathogenic and 13 uncertain variants in JAK2 have source records linked to Thrombocythemia 2. Association strength is not clinical gene validity.
SH2B3: SH2B adapter protein 3
It restrains cytokine and growth-factor signaling in hematopoietic cells, including JAK-STAT pathways controlling blood-cell production. Loss-of-function variants can increase blood-cell proliferation and predispose to myeloproliferative neoplasms, while common variants influence autoimmune and hematologic traits.
0 ClinVar pathogenic / likely pathogenic and 4 uncertain variants in SH2B3 have source records linked to Thrombocythemia 2. Association strength is not clinical gene validity.
CALR: Calreticulin
It assists glycoprotein folding and buffers calcium within the endoplasmic reticulum. Somatic frameshift variants create abnormal C termini that activate thrombopoietin-receptor signaling and are major drivers of essential thrombocythemia and primary myelofibrosis.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CALR have source records linked to Thrombocythemia 2. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Thrombocythemia 2
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| MPL F104S | 104 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL P136H | 136 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL P136R | 136 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL W154R | 154 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL P635L | 635 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| MPL R102P | 102 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL P106L | 106 | Extracellular | Pathogenic / likely pathogenic (★★) |
| JAK2 R938Q | 938 | Protein kinase 2 | Pathogenic / likely pathogenic (★) |
| JAK2 V617I | 617 | Protein kinase 1 | Pathogenic / likely pathogenic |
Which prediction tools work for Thrombocythemia 2
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- REVEL: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 91 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 90 out of 100
- AlphaMissense: 88 out of 100
- ESM1b (LLR): 85 out of 100
- phyloP: 84 out of 100
- CADD: 80 out of 100
- SpliceAI: 49 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 47 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Congenital amegakaryocytic thrombocytopenia also has ClinVar records linked to MPL variants; they fall mostly in different places as the Thrombocythemia 2 variants (19 pathogenic / likely pathogenic).
- Essential thrombocythemia also has ClinVar records linked to MPL variants; they fall partly in the same places as the Thrombocythemia 2 variants (8 pathogenic / likely pathogenic).
Diseases related to Thrombocythemia 2
- Primary myelofibrosis, also linked to CALR, JAK2, MPL and SH2B3
- Essential thrombocythemia, also linked to JAK2 and MPL
- Primary familial polycythemia due to EPO receptor mutation, also linked to JAK2 and SH2B3
- Acute myeloid leukemia, also linked to JAK2
- Congenital amegakaryocytic thrombocytopenia, also linked to MPL
- Crohn disease, also linked to JAK2
- Type 1 diabetes mellitus, also linked to SH2B3
- Hypothyroidism, also linked to SH2B3
- Inflammatory bowel disease, also linked to JAK2
- Myocardial infarction, also linked to SH2B3
- Ischemic stroke, also linked to SH2B3
Frequently asked questions
Which genes have records linked to Thrombocythemia 2?
This view contains 4 analyzed proteins: MPL, JAK2, SH2B3, CALR. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 9 pathogenic or likely pathogenic variants, 18 variants of uncertain significance and 3 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 39 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center